An update on molecularly targeted therapies in second- and third-line treatment in non-small cell lung cancer: focus on EGFR inhibitors and anti-angiogenic agents (Q38077494)

From Wikidata

Jump to navigation Jump to search

scientific article published on 29 January 2013

Language	Label	Description	Also known as
English	An update on molecularly targeted therapies in second- and third-line treatment in non-small cell lung cancer: focus on EGFR inhibitors and anti-angiogenic agents	scientific article published on 29 January 2013

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

1 reference

Europe PubMed Central

An update on molecularly targeted therapies in second- and third-line treatment in non-small cell lung cancer: focus on EGFR inhibitors and anti-angiogenic agents (English)

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

angiogenesis inhibitor

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

M Majem

1

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

C Pallarès

2

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

publication date

29 January 2013

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

Clinical and Translational Oncology

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

15

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

5

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

343-357

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

Non–Small Cell Lung Cancer

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0964-2

21 January 2018

Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0964-2

21 January 2018

Metastatic non-small-cell lung cancer: consensus on pathology and molecular tests, first-line, second-line, and third-line therapy: 1st ESMO Consensus Conference in Lung Cancer; Lugano 2010.

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0964-2

21 January 2018

The efficacy of pemetrexed as a third- or fourth-line therapy and the significance of thymidylate synthase expression in patients with advanced non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0964-2

21 January 2018

Clinical predictive factors for advanced non-small cell lung cancer (NSCLC) patients receiving third-line therapy: Selecting the unselectable?

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0964-2

21 January 2018

Somatic mutations affect key pathways in lung adenocarcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0964-2

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0964-2

21 January 2018

Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0964-2

21 January 2018

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0964-2

21 January 2018

Epidermal growth factor receptor mutations in lung cancer

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0964-2

21 January 2018

Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0964-2

21 January 2018

Detection of mutations in EGFR in circulating lung-cancer cells

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0964-2

21 January 2018

Afatinib (BIBW 2992) Development in Non-Small-Cell Lung Cancer

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0964-2

21 January 2018

BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0964-2

21 January 2018

A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumours

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0964-2

21 January 2018

Phase I trial of the irreversible EGFR and HER2 kinase inhibitor BIBW 2992 in patients with advanced solid tumors

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0964-2

21 January 2018

Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0964-2

21 January 2018

Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0964-2

21 January 2018

EKB-569, a new irreversible epidermal growth factor receptor tyrosine kinase inhibitor, with clinical activity in patients with non-small cell lung cancer with acquired resistance to gefitinib

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0964-2

21 January 2018

Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0964-2

21 January 2018

A phase I study with neratinib (HKI-272), an irreversible pan ErbB receptor tyrosine kinase inhibitor, in patients with solid tumors

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0964-2

21 January 2018

Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: results of a phase II trial in patients with advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0964-2

21 January 2018

CI-1033, an irreversible pan-erbB receptor inhibitor and its potential application for the treatment of breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0964-2

21 January 2018

Multicenter, randomized, phase II trial of CI-1033, an irreversible pan-ERBB inhibitor, for previously treated advanced non small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0964-2

21 January 2018

Randomized phase II multicenter trial of two schedules of lapatinib as first- or second-line monotherapy in patients with advanced or metastatic non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0964-2

21 January 2018

PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0964-2

21 January 2018

Phase I dose-escalation study of the pan-HER inhibitor, PF299804, in patients with advanced malignant solid tumors

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0964-2

21 January 2018

Tumor angiogenesis: therapeutic implications

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0964-2

21 January 2018

Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0964-2

21 January 2018

Vascular endothelial growth factor: basic science and clinical progress

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0964-2

21 January 2018

PDGF and vessel maturation

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0964-2

21 January 2018

Angiogenesis inhibition in cancer therapy: platelet-derived growth factor (PDGF) and vascular endothelial growth factor (VEGF) and their receptors: biological functions and role in malignancy

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0964-2

21 January 2018

Prognostic impact of angiogenic markers in non-small-cell lung cancer is related to tumor size

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0964-2

21 January 2018

Angiogenesis in non-small cell lung cancer: the prognostic impact of neoangiogenesis and the cytokines VEGF and bFGF in tumours and blood.

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0964-2

21 January 2018

Distinct patterns of cytokine and angiogenic factor modulation and markers of benefit for vandetanib and/or chemotherapy in patients with non-small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0964-2

21 January 2018

Baseline vascular endothelial growth factor concentration as a potential predictive marker of benefit from vandetanib in non-small cell lung cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0964-2

21 January 2018

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0964-2

21 January 2018

Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0964-2

21 January 2018

Randomized phase II study of vandetanib alone or with paclitaxel and carboplatin as first-line treatment for advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0964-2

21 January 2018

Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0964-2

21 January 2018

Phase III Trial of Vandetanib Compared With Erlotinib in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0964-2

21 January 2018

Vandetanib plus pemetrexed for the second-line treatment of advanced non-small-cell lung cancer: a randomized, double-blind phase III trial

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0964-2

21 January 2018

Rhebbing up mTOR: New Insights on TSC1 and TSC2, and the Pathogenesis of Tuberous Sclerosis

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0964-2

21 January 2018

Phase II study of continuous daily sunitinib dosing in patients with previously treated advanced non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0964-2

21 January 2018

Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0964-2

21 January 2018

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0964-2

21 January 2018

BAY 43-9006 inhibition of oncogenic RET mutants

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0964-2

21 January 2018

Sorafenib: a clinical and pharmacologic review

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0964-2

21 January 2018

Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0964-2

21 January 2018

Phase II, multicenter, uncontrolled trial of single-agent sorafenib in patients with relapsed or refractory, advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0964-2

21 January 2018

Randomized, Double-Blind, Placebo-Controlled, Phase II Trial of Sorafenib and Erlotinib or Erlotinib Alone in Previously Treated Advanced Non–Small-Cell Lung Cancer

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0964-2

21 January 2018

BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0964-2

21 January 2018

Phase I Safety, Pharmacokinetic, and Biomarker Study of BIBF 1120, an Oral Triple Tyrosine Kinase Inhibitor in Patients with Advanced Solid Tumors

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0964-2

21 January 2018

BIBF 1120 for the treatment of non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0964-2

21 January 2018

Phase I open-label study of continuous treatment with BIBF 1120, a triple angiokinase inhibitor, and pemetrexed in pretreated non-small cell lung cancer patients

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0964-2

21 January 2018

A phase II double-blind study to investigate efficacy and safety of two doses of the triple angiokinase inhibitor BIBF 1120 in patients with relapsed advanced non-small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0964-2

21 January 2018

Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0964-2

21 January 2018

Efficacy and safety of axitinib in patients with advanced non-small-cell lung cancer: results from a phase II study.

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0964-2

21 January 2018

AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0964-2

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0964-2

21 January 2018

Randomized, double-blind trial of carboplatin and paclitaxel with either daily oral cediranib or placebo in advanced non-small-cell lung cancer: NCIC clinical trials group BR24 study

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0964-2

21 January 2018

Phase I evaluation of cediranib, a selective VEGFR signalling inhibitor, in combination with gefitinib in patients with advanced tumours

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0964-2

21 January 2018

Phase 1b study of motesanib, an oral angiogenesis inhibitor, in combination with carboplatin/paclitaxel and/or panitumumab for the treatment of advanced non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0964-2

21 January 2018

Pazopanib: a novel multitargeted tyrosine kinase inhibitor

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0964-2

21 January 2018

Phase II proof-of-concept study of pazopanib monotherapy in treatment-naive patients with stage I/II resectable non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0964-2

21 January 2018

Angiogenesis as a Prognostic Indicator of Survival in Non-Small-Cell Lung Carcinoma: a Prospective Study

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0964-2

21 January 2018

Phase I study of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor, in patients with advanced solid tumors

1 reference

https://pubmed.ncbi.nlm.nih.gov/23359171

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker

1 reference

https://pubmed.ncbi.nlm.nih.gov/23359171

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II study of sunitinib in patients with non-small cell lung cancer and irradiated brain metastases.

1 reference

https://pubmed.ncbi.nlm.nih.gov/23359171

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The effect of dacomitinib (PF-00299804) on CYP2D6 activity in healthy volunteers who are extensive or intermediate metabolizers

1 reference

https://pubmed.ncbi.nlm.nih.gov/23359171

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Expression of vascular endothelial growth factor (VEGF) and association with microvessel density in small-cell and non-small-cell lung carcinomas

1 reference

https://pubmed.ncbi.nlm.nih.gov/23359171

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

International, randomized, placebo-controlled, double-blind phase III study of motesanib plus carboplatin/paclitaxel in patients with advanced nonsquamous non-small-cell lung cancer: MONET1.

1 reference

https://pubmed.ncbi.nlm.nih.gov/23359171

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The need for third-line treatment in non-small cell lung cancer: an overview of new options.

1 reference

https://pubmed.ncbi.nlm.nih.gov/23359171

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Co-expression of PDGF-B and VEGFR-3 strongly correlates with lymph node metastasis and poor survival in non-small-cell lung cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/23359171

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Vandetanib Versus placebo in patients with advanced non-small-cell lung cancer after prior therapy with an epidermal growth factor receptor tyrosine kinase inhibitor: a randomized, double-blind phase III trial (ZEPHYR)

1 reference

https://pubmed.ncbi.nlm.nih.gov/23359171

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/23359171

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Sunitinib plus erlotinib versus placebo plus erlotinib in patients with previously treated advanced non-small-cell lung cancer: a phase III trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/23359171

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phosphorylation of extracellular signal-regulated kinase 1 and 2, protein kinase B, and signal transducer and activator of transcription 3 are differently inhibited by an epidermal growth factor receptor inhibitor, EKB-569, in tumor cells and normal

1 reference

https://pubmed.ncbi.nlm.nih.gov/23359171

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A phase I evaluation of oral CI-1033 in combination with paclitaxel and carboplatin as first-line chemotherapy in patients with advanced non-small cell lung cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/23359171

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Vascular endothelial growth factor is associated with neovascularization and influences progression of non-small cell lung carcinoma.

1 reference

https://pubmed.ncbi.nlm.nih.gov/23359171

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Antiangiogenic therapy: a universal chemosensitization strategy for cancer?

1 reference

https://pubmed.ncbi.nlm.nih.gov/23359171

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Symptom and quality of life benefit of afatinib in advanced non-small-cell lung cancer patients previously treated with erlotinib or gefitinib: results of a randomized phase IIb/III trial (LUX-Lung 1).

1 reference

https://pubmed.ncbi.nlm.nih.gov/23359171

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Vascular endothelial growth factor 189 mRNA isoform expression specifically correlates with tumor angiogenesis, patient survival, and postoperative relapse in non-small-cell lung cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/23359171

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration.

1 reference

https://pubmed.ncbi.nlm.nih.gov/23359171

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S12094-012-0964-2

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38077494&oldid=2201242320"